multiple myeloma
Conditions
Interventions
Experimental group: Isazomi+cyclophosphamide+ dexamethasone
Control group:Isazomi+dexamethasone
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Untreated primary diagnosis of multiple myeloma according to IMWG criteria; 2. According to the IMWG standard disease can be measured: there are evaluable blood and urine M protein indicators (serum M-protein >=1g/dL (>=10 g/L), if subjects are IgA, IgD, IgE or IgM multiple myeloma, >=0.5 g/dL;Or urine M-protein level >=200 mg/24 h;Or light chain multiple myeloma, no measured lesion in serum or urine, serum immunoglobulin free light chain (FLC) >=10 mg/dL and serum immunoglobulin Kappa /lambda FLC ratio abnormal);Or there may be measurable extramedullary mass; 3. Aged 65 years old or above, or vulnerable patients; 4. The informed consent has been signed; 5. During the whole study period, the patients can regularly go to the research institution for relevant testing, evaluation and management.
Exclusion criteria
Exclusion criteria: 1. Patients who are known to be allergic to any study drug, its analogues, or excipients of different formulations in any preparation; 2. Patients with acute myocardial infarction, acute heart failure, acute cerebral infarction or acute cerebral hemorrhage and other cardiovascular and cerebrovascular events occurred within the last half month; 3. Patients who received live attenuated vaccine within 4 weeks before drug administration were studied for the first time; 4. Patients who are participating in other clinical trials; 5. Inability to understand or follow the research plan.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Overall Response Rate; | — |
Countries
China
Contacts
Public ContactGong Yuping
Department of Hematology, West China Hospital, Sichuan University
Outcome results
None listed